A Phase 3 interventional study of Dexamethasone and Placebo Vehicle in Post-Surgical Ocular Pain and Post-Surgical Ocular Inflammation, sponsored by Ocular Therapeutix, Inc.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-11-13.
Sponsored by Ocular Therapeutix, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies testing dexamethasone in Pain — 9 open to participants now, 10 under way, 2 of them phase 3. Dexamethasone · Pain.
Among the 64 studies testing dexamethasone in Pain, this one has the largest enrollment, is one of 3 that started in 2015, is one of 9 in phase 3, and was the 32nd registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →9 of the 64 studies testing dexamethasone in Pain are open now, in 7 countries. Recruiting first, the newest first:
Elsan · Sites in France
Ages 18+
Nishtar Medical University · Sites in Pakistan
Ages 18–40
Balgrist University Hospital · Sites in Switzerland
Ages 18–99 · Healthy volunteers
Dow University of Health Sciences · Sites in Pakistan
Ages 18–50 · Healthy volunteers
Wake Forest University Health Sciences · Sites in United States
Ages 18+
By country, each count listing its studies:
Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 9 · Phase 4 29
First in 2005; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 438 is above the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 89 across the 64 interventional studies. Of the 42 that completed or were terminated, 16 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 64 have an industry lead sponsor. The 10 most frequent:
Ocular Therapeutix, Inc. is the lead sponsor of 33 studies on the registry; 2 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
Ocular Therapeutix, Inc. has 4 studies filed under Pain — fewer than ten, so there is no comparison to draw.
2 of the studies testing dexamethasone in Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07208799Nishtar Medical UniversityComparison of Submucosal Dexamethasone and Methylprednisolone in Postoperative Sequelae of Parasymphsis Fractures | 2026-11-30 |
| NCT07097493Wake Forest University Health SciencesLiposomal Bupivacaine vs Perineural Adjuvants in Adductor Canalf and iPACK Blocks in Total Knee Arthroplasty | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 64 studies testing dexamethasone in Pain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of the study was to evaluate the safety and efficacy of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of post-surgical inflammation and pain in subjects who had undergone cataract extraction with intraocular lens implantation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
Drug: Dexamethasone
PV (placebo drug delivery vehicle)
Other: Placebo Vehicle
Absence of Anterior Chamber Inflammation
Absence of cells (i.e., score of '0') in the anterior chamber of the study eye at Day 14
Time frame: Day 14
Absence of Ocular Pain
Absence of pain (i.e., score of '0') in the study eye at Day 8
Time frame: Day 8
| Milestone | OTX-DP | Placebo Vehicle |
|---|---|---|
| Started | 216 | 222 |
| Completed | 214 | 221 |
| Not completed | 2 | 1 |
Absence of cells (i.e., score of '0') in the anterior chamber of the study eye at Day 14
| percentage of total participants | OTX-DP | Placebo Vehicle |
|---|---|---|
| Absence of Anterior Chamber Inflammation | 52.3 | 31.1 |
Absence of pain (i.e., score of '0') in the study eye at Day 8
| percentage of total participants | OTX-DP | Placebo Vehicle |
|---|---|---|
| Absence of Ocular Pain | 79.6 | 61.3 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OTX-DP | 0/216 (0%) | 3/216 (1.4%) | 63/216 (29.2%) |
| Placebo Vehicle | 0/221 (0%) | 2/221 (0.9%) | 86/221 (38.9%) |
| Event | OTX-DP | Placebo Vehicle |
|---|---|---|
| Retinal detachmentEye disorders | 1/216 | 0/221 |
| Cardiac failure acuteCardiac disorders | 1/216 | 0/221 |
| Lower gastrointestinal hemorrhageGastrointestinal disorders | 1/216 | 0/221 |
| NephrolithiasisRenal and urinary disorders | 0/216 | 1/221 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/216 | 1/221 |
| Event | OTX-DP | Placebo Vehicle |
|---|---|---|
| Adverse EventsGeneral disorders | 63/216 | 86/221 |
All randomized subjects
| Age, Continuous(years) | OTX-DP | Placebo Vehicle | Total |
|---|---|---|---|
| Mean | 67.3 ± 9.09 | 68.6 ± 8.37 | 68.0 ± 8.75 |
| Sex: Female, Male(Participants) | OTX-DP | Placebo Vehicle | Total |
|---|---|---|---|
| Female | 120 | 130 | 250 |
| Male | 96 | 92 | 188 |
| Ethnicity (NIH/OMB)(Participants) | OTX-DP | Placebo Vehicle | Total |
|---|---|---|---|
| Hispanic or Latino | 37 | 37 | 74 |
| Not Hispanic or Latino | 179 | 185 | 364 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | OTX-DP | Placebo Vehicle | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 2 | 4 |
| Asian | 8 | 1 | 9 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 |
| Black or African American | 28 | 25 | 53 |
| White | 174 | 189 | 363 |
| More than one race | NA | NA | NA |
| Unknown or Not Reported | 3 | 4 | 7 |
| Iris Color(Participants) | OTX-DP | Placebo Vehicle | Total |
|---|---|---|---|
| Brown | 106 | 101 | 207 |
| Blue | 61 | 64 | 125 |
| Hazel | 32 | 37 | 69 |
| Green | 15 | 18 | 33 |
| Gray | 2 | 0 | 2 |
| Black | 0 | 2 | 2 |
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2015 to primary completion in May 2016, 7 months.
Results were first posted in Oct 2017, 1 year 5 months after primary completion.
Of 105 industry-sponsored phase 3 interventional studies under Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 23. This study's 7 months is below that.
Counting every sponsor, half of 216 studies reached it within 18 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone